超选眼动脉化疗治疗视网膜母细胞瘤的临床观察  

Clinical observation on superselective ophthalmic artery chemotherapy for retinoblastoma

作　　者：彭昌福[1] 李俊杰[1] 段国平[1] 

机构地区：[1]湖南省人民医院眼科,中国湖南省长沙市410005

出　　处：《国际眼科杂志》2013年第12期2519-2521,共3页International Eye Science

基　　金：长沙市科技计划民生科技支撑资金专项(No.K1106037-31)~~

摘　　要：目的:通过对视网膜母细胞瘤(retinoblastoma,RB)患者实施眼动脉化疗,观察化疗效果及副反应。方法:根据RB最新国际分期,对11例11眼A^D期RB患者,通过股动脉插管至眼动脉,使用马法兰(melphalan)经眼动脉灌注,对RB患者实施动脉化疗。结果:所选患者共实施眼动脉灌注化疗23次,随访3~12mo,其中8例肿瘤明显缩小、钙化,2例病情进展,实施眼球摘除,1例失访。除部分患者术后短暂的恶心、呕吐、发热,没有出现死亡、中风、骨髓抑制等严重并发症。结论:所选患者中,A、B、C期9例,7例有效,1例继续进展,1例失访,有效率88%;2例D期患者1例有效,1例继续进展,有效率50%。AIM： To observe the efficacy and side reaction of superselective ophthalmic artery chemotherapy for retinoblastoma （ RB） . METHODS：Eleven cases （11 eyes） of RB, ranging from stage A to D according to the latest International Intraocular Retinoblastoma classification, were treated with melphalan infusion by the ophthalmic artery. RESULTS： Such intra -arterial chemotherapy was administered for 23 times and the patients were followed up for 3-12 months.During the follow-up, 8 cases were effective with significant tumor shrinking and calcification;2 patients progressed and received enucleation of eyeballs; 1 case was lost to follow-up. Postoperative transient nausea, vomiting and fever appeared in some cases, but serious complications were not found, such as death, stroke, myelosuppression,etc. CONCLUSION：Among 9 cases from group A, B and C, 7 cases were effective, 1 case continued to progress and 1 case was lost to follow-up, and the effective rate was 88%.In the 2 cases of group D, 1 case was effective and the other continueed to progress, so the effective rate was 50%.

关 键 词：动脉化疗 马法兰 视网膜母细胞瘤 

分 类 号：R739.7[医药卫生—肿瘤]